Mar 16, 2022
AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
Mar 09, 2022
AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting
Mar 09, 2022
AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting
Mar 08, 2022
AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer
Mar 07, 2022
AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance Pipeline
Mar 03, 2022
AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer
Jan 26, 2022
AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar
Jan 24, 2022
AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer
Jan 19, 2022
AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference
Dec 09, 2021
AIM ImmunoTech's Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza
 6   7   8   9   10     11    12   13   14   15   16 
 <<   <   >   >>